Breakthrough VISTA Cancer Drug Data: Sensei Bio to Reveal Results for Treatment-Resistant Tumors Sensei Biotherapeutics announces Oct 20 KOL event featuring Phase 1/2 data for Solnerstotug in PD-(L)1 resistant tumors. Dr. Papadopoulos to discuss treatment landscape and Phase 2 plans. stocktitan.net stocktitan.net / feeds stocktitan-net / / #money / / 22 days 22d Share
